In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catherine Longworth

Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!

Latest From Catherine Longworth

MeMed Ready To Partner On IVD Technology That Can Cut Antibiotic Overuse

MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.

Diagnostics Commercial

Medtronic Sales Slump In Q4 2020 But CEO Reveals Appetite For Tuck-In Acquisitions

Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.

Coronavirus COVID-19 Sales & Earnings

Investor Eye: Sergey Young Searches For Investments That Extend Life

Sergey Young is on a mission to "extend healthy lifespans" by investing in longevity breakthroughs. Last year, the venture capitalist established a $100m fund investing in technologies with the potential to improve healthy long living.

Investor Eye Financing

‘Diagnostics Has Been Underestimated’: COVID-19 Testing Drives Roche Diagnostics Q1 Sales

Roche's diagnostics sales increased 5% to $2.93bn in the first quarter of 2020. Molecular diagnostics was the main growth contributor, driven by demand for COVID-19 tests and automated testing systems.

In Vitro Diagnostics Sales & Earnings

Start-Up Spotlight: BrainQ Forsees New Era For Neurodisorder Treatment

Israeli start-up BrainQ has a vision of helping paralyzed neurodisorder patients regain motor function. The clinical-stage company is developing an AI-based wearable system for at-home treatment of neurodisorders. 

Start-up Spotlight StartUps and SMEs

Device Week: COVID-19 Impact On J&J In Q1 2020; Dexcom, Abbott CGMs Make Way Into Hospitals

In this week's podcast, Medtech Insight’s Reed Miller discusses the impact of COVID-19 on Johnson & Johnson’s medical device businesses in Q1 2020. And Marion Webb explains Abbott and Dexcom's plans to bring continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients.

Device Week Coronavirus COVID-19
See All
UsernamePublicRestriction

Register